Total Health

 

Total Health is the largest provider of free cancer care resources for people who are treating or living with cancer. Our programs arm cancer care teams with the latest research and strategies to improve patient outcomes.

For more info visit our website at Total Health.

 

2020 Virtual ESMO Review
I

2020 ESMO Update on ALK+ NSCLC: PFS Data With Lorlatinib vs. Crizotinib - Should We Consider Lorlatinib a New 1L Option?

By 2020 Virtual ESMO Review FEATURING Ibiayi Dagogo-Jack
By 2020 Virtual ESMO Review FEATURING Ibiayi Dagogo-Jack
225 views
November 11, 2020
0 Comments
Login to view comments. Click here to Login

Featured Video

20:09
AstraZeneca Oncology

Management Strategies for Anemia in First-line Maintenance Therapy f…

Feat. D. Czel, C. Arn

Featured Video

06:51
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Prevalence and Prediction of Ruxolitinib Tr…

Feat. D. Tremblay
2020 Virtual ESMO Review
05:09
2020 Virtual ESMO Review

2020 ESMO Update on R/R DLBCL: Does AUTO3 + Pembro Induce CRs? What …

Feat. J. Amengual
07:49
2020 Virtual ESMO Review

2020 ESMO Update on R/R cHL: How Effective Is Brentuximab Vedotin?

Feat. J. Amengual
06:52
2020 Virtual ESMO Review

2020 ESMO Update on Non-Hodgkin Lymphomas: Does BETi CC-90010 Lead t…

Feat. J. Amengual
07:33
2020 Virtual ESMO Review

2020 ESMO Update on Targeted Therapy in NSCLC: Does ADAURA Trial Sug…

Feat. I. Dagogo-Jack
05:44
2020 Virtual ESMO Review

2020 ESMO Update on Targeted Therapy in NSCLC: Can We Safely Combine…

Feat. I. Dagogo-Jack
06:52
2020 Virtual ESMO Review

2020 ESMO Update on UC: Does 1L Durvalumab +/- Tremelimumab Improve …

Feat. M. Bupathi
08:30
2020 Virtual ESMO Review

2020 ESMO Update on RCC: Is IO + TKI Option Effective in Advanced Di…

Feat. M. Bupathi
07:47
2020 Virtual ESMO Review

2020 ESMO Update on Advanced UC: Does the Addition of Avelumab 1L Ma…

Feat. M. Bupathi
11:16
2020 Virtual ESMO Review

2020 ESMO Update on ALK+ NSCLC: PFS Data With Lorlatinib vs. Crizoti…

Feat. I. Dagogo-Jack
20:42
2020 Virtual ESMO Review

ESMO 2020 Update on mPC: How Beneficial Is Abiraterone+/-Ipatasertib…

Feat. T. Barauskas Dorff
33:00
Total Health

Will COVID-19 Leave Its Mark on Cancer Care?

Feat. G. Lopes
08:53
2020 Virtual ESMO Review

2020 ESMO Updates on Pembrolizumab & Cemiplimab: Can mNSCLC Be C…

Feat. M. Dietrich
06:15
2020 Virtual ESMO Review

2020 ESMO First Results from PIONeeR Project on Biomarkers in Advanc…

Feat. M. Dietrich
09:56
2020 Virtual ESMO Review

2020 ESMO Updates in Lung Cancer: Does 1L Nivolumab–Ipilimumab Boost…

Feat. M. Dietrich
07:30
2020 Virtual ESMO Review

2020 ESMO Update on MBC: Is There OS Benefit to Alpelisib + Fulvestr…

Feat. J. Crozier
10:12
2020 Virtual ESMO Review

2020 ESMO Update on MBC: Does the Addition of Tamoxifen to Abemacicl…

Feat. J. Crozier
08:19
2020 Virtual ESMO Review

2020 ESMO Update on Immune Checkpoint Inhibitors in eTNBC: Does the …

Feat. L. Schwartzberg
06:06
2020 Virtual ESMO Review

2020 ESMO Update on CDK 4/6 in Adjuvant HR+, HER2- EBC: Does the Add…

Feat. L. Schwartzberg
07:46
2020 Virtual ESMO Review

2020 ESMO Update on CDK 4/6 in Adjuvant HR+, HER2- EBC: How Does Two…

Feat. L. Schwartzberg
13:27
2020 Virtual ESMO Review

2020 ESMO Update on mPDAC: Does the Addition of Dual Immune Checkpoi…

Feat. L. Connell
08:07
2020 Virtual ESMO Review

2020 ESMO Update on Metastatic Pancreatic Cancer: What Does the Qoli…

Feat. L. Connell